Submodule
Appropriateness, Timing, and Goals
Parenteral nutrition is reserved for a patient whose nutrition needs cannot be met safely or sufficiently through the gastrointestinal tract.
- Indications and alternatives
- Nutrition risk and timing
- Hemodynamic readiness
- Goals, ethics, and reassessment
Oral and enteral intake cannot meet the clinical target
→Digestion, absorption, or intestinal access is inadequate
→Nutrition risk and expected duration justify intravenous support
→Hemodynamics and metabolic abnormalities can be managed safely
Require both need and route failure
Parenteral nutrition delivers amino acids, dextrose, lipid, electrolytes, vitamins, trace elements, and water directly into the circulation. It is appropriate when clinically important nutrition needs exist and oral or enteral delivery is impossible, contraindicated, or persistently insufficient. A central line that already exists is not an indication by itself.
Recognize common indications
Examples include intestinal obstruction or severe dysmotility, major malabsorption, short bowel syndrome, high-output fistula without usable distal access, prolonged ileus, and selected cases of severe pancreatitis or gastrointestinal bleeding when enteral delivery fails. The diagnosis alone does not settle the decision. Anatomy, absorption, severity, expected duration, and realistic alternatives still matter.
Time therapy to nutrition risk
A patient with severe malnutrition or high nutrition risk may need parenteral support earlier when enteral delivery is not feasible. A stable, well-nourished adult can often tolerate a longer period of inadequate intake before PN is started. Timing is individualized and should account for cumulative intake, disease trajectory, procedural plans, and likelihood that the gut will become usable.
Stabilize before aggressive delivery
Severe metabolic derangement, uncontrolled shock, and major fluid or electrolyte abnormalities can make immediate full-dose PN unsafe. Correct or actively manage instability, identify refeeding risk, and introduce energy deliberately. Nutrition support is a treatment with measurable benefits, burdens, and stopping criteria, so goals and patient preferences belong in the decision.
Quick check
Submodule
Venous Access and Catheter Safety
The final admixture concentration, expected duration, vascular anatomy, infection risk, and care setting determine the access strategy.
- Peripheral versus central delivery
- PICC, tunneled catheter, and port
- Tip location and line integrity
- Infection and thrombosis prevention
Lower osmolarity, larger volume, frequent site review
→Central tip with insertion and thrombosis considerations
→Durable external access for selected home therapy
→Intermittent access with needle and care requirements
Use peripheral PN as a limited bridge
Peripheral PN is most useful for short-term or supplemental therapy when nutrient goals can fit inside a lower-osmolarity, higher-volume formulation. It is limited by vein tolerance, fluid requirements, phlebitis, infiltration, and the possibility that dilution prevents adequate protein or energy delivery. Osmolarity limits are protocol and access specific, so a single universal cutoff should not replace local validation.
Use central access for concentrated therapy
Central venous access permits higher final concentrations because rapid blood flow dilutes the admixture. A peripherally inserted central catheter, nontunneled catheter, tunneled catheter, or implanted port may be selected according to expected duration, urgency, anatomy, thrombosis risk, care setting, and patient capacity. Preserve future dialysis access when chronic kidney disease makes that relevant.
Confirm and protect the system
The catheter tip and device function must be confirmed according to device, insertion method, and facility policy before use. Use the fewest lumens necessary, dedicate a lumen to PN when feasible, minimize connections and manipulations, and avoid routine medication coadministration. A compatibility check does not remove infection risk.
Treat line findings as clinical signals
Fever, chills during infusion, erythema, drainage, tenderness, resistance, arm or neck swelling, catheter migration, or unexplained loss of function requires prompt assessment. Hand hygiene, aseptic hub access, appropriate skin antisepsis, dressing care, and daily review of line necessity are central to prevention. Routine systemic antibiotics or anticoagulants are not used solely to prevent catheter infection.
Quick check
Submodule
Macronutrient and Fluid Design
A safe prescription integrates protein, dextrose, lipid, non-PN energy, fluid, organ function, and the patient's metabolic capacity.
- Amino acids and nitrogen
- Dextrose and glucose infusion rate
- Lipid injectable emulsions
- Energy, fluid, and non-PN calories
Match protein to illness, losses, organ support, and goals
→Check glucose infusion rate and glycemic tolerance
→Account for essential fatty acids and non-PN calories
→Fit the nutrient plan inside the fluid prescription
Set protein from clinical demand
Amino acids provide 4 kcal per gram but are prescribed primarily to support protein synthesis and limit net protein loss. Requirements vary with illness severity, wounds, gastrointestinal losses, renal replacement therapy, obesity, liver disease, and goals of care. Do not automatically restrict protein solely because kidney or liver dysfunction is present. Base changes on the full clinical state and current guidance.
Advance dextrose within metabolic capacity
Dextrose provides 3.4 kcal per gram. The glucose infusion rate links grams, weight, and infusion time, making an excessive carbohydrate load visible. Hyperglycemia, excess carbon dioxide production, fluid retention, fatty liver, and hypertriglyceridemia can signal overfeeding or poor tolerance. Account for dextrose in intravenous fluids and medications.
Prescribe lipid as a drug product
Lipid injectable emulsions provide energy and essential fatty acids, but composition, concentration, maximum rate, allergy information, age indication, and compatibility are product specific. Count lipid from propofol and clevidipine. Monitor triglycerides and clinical tolerance. Current ASPEN adult guidance recommends limiting or holding ILE when triglycerides exceed 400 mg per dL, while avoiding prolonged lipid omission that can cause essential fatty acid deficiency.
Make volume and route agree
The total volume must include macronutrient stock solutions, electrolytes, vitamins, trace elements, medications added to the bag, and sterile water. A fluid-restricted patient may require central access and a more concentrated formulation. A patient with high gastrointestinal or renal losses may need additional replacement outside PN. Avoid treating a generic milliliter-per-kilogram estimate as a fixed prescription.
Quick check
Submodule
Electrolytes, Vitamins, and Trace Elements
Micronutrient dosing begins with standard adult needs, then changes with organ function, measured deficits, abnormal losses, duration, and product availability.
- Electrolyte pattern and acid base
- Parenteral multivitamins
- Trace elements and toxicity
- Shortages and individualized supplementation
Kidney function, acid base state, losses, and medicines
→Use an age-appropriate complete parenteral product when available
→Cholestasis, kidney failure, wounds, diarrhea, and duration matter
→Use current ASPEN and ASHP guidance, not a permanent workaround
Prescribe electrolytes as a pattern
Sodium, potassium, magnesium, calcium, phosphate, chloride, and acetate must be interpreted with kidney function, urine output, gastrointestinal losses, medications, acid-base status, and current replacement. Chloride and acetate can shift the delivered acid-base load. Bicarbonate is not a routine PN additive. Standard ranges are starting references, not permission to ignore a changing patient.
Protect calcium and phosphate compatibility
Calcium-phosphate precipitation can be fatal and cannot be predicted safely from a single concentration rule. Risk changes with the calcium salt, phosphate salt, amino acid product and concentration, dextrose concentration, pH, temperature, order of mixing, final volume, and storage. Use validated product-specific compatibility data and compounding software, add phosphate early and calcium late when required by the validated process, and inspect the final preparation.
Provide complete vitamins
A complete age-appropriate parenteral multivitamin is generally included daily. Vitamins can be light sensitive and chemically unstable, so storage, protection, and manufacturer instructions matter. Additional thiamine is important in patients at refeeding risk or with high requirements. During shortages, conserve and substitute according to current ASPEN and ASHP recommendations instead of making an old crisis schedule permanent.
Individualize trace elements
Multi-trace products commonly provide zinc, copper, manganese, selenium, and chromium in varying amounts. Increase selected elements for documented high losses, burns, wounds, or renal replacement therapy. Reduce or omit selected elements when cholestasis or organ dysfunction creates accumulation risk, then reassess to avoid deficiency. Routine iron addition to a total nutrient admixture is avoided because of compatibility and safety concerns.
Quick check
Submodule
Formulation, Compounding, and Administration Safety
Parenteral nutrition is a high-alert compounded sterile preparation whose physical, chemical, microbial, and labeling safety must be verified as one system.
- Two-in-one and total nutrient admixtures
- Emulsion stability
- USP sterile compounding
- Filtration, labeling, and final verification
Dose, units, route, sequence, allergies, and clinical fit
→Product-specific calcium, phosphate, pH, and emulsion compatibility
→Particles, precipitate, oiling, leakage, label, and final composition
→Current ASPEN recommendation for all PN formulations
Choose a formulation deliberately
A two-in-one admixture contains dextrose and amino acids, with lipid infused separately. A total nutrient admixture also contains lipid in the same container. The TNA can simplify administration but creates additional emulsion-stability constraints and can obscure some particles. The choice affects compatibility, inspection, tubing, hang time, and workflow.
Recognize emulsion failure
Lipid droplets are stabilized by electrostatic forces. Excess cations, unfavorable pH, inappropriate concentrations, temperature, time, and incompatible additives can promote aggregation, coalescence, or irreversible cracking. Visible oiling, free oil, precipitate, particles, unusual color, leakage, or a damaged container requires quarantine and investigation. Do not rely on appearance alone to prove compatibility.
Apply current sterile-compounding standards
PN compounding must follow the current official USP chapter 797, applicable law, manufacturer instructions, and facility quality systems. The lecture's former low, medium, and high risk categories and its fixed beyond-use times are obsolete. Beyond-use dating must reflect the current category, environment, process, sterility assurance, stability data, container, and storage conditions.
Filter every PN formulation
ASPEN now recommends a 1.2 micron in-line filter for total nutrient admixtures, dextrose-amino acid admixtures, and separate lipid emulsions. This replaces the older 0.22 micron convention for lipid-free PN. Place and prime the filter according to the formulation and manufacturer instructions. Avoid medication coadministration; when unavoidable, obtain a pharmacist compatibility assessment and use the correct connection and flushing process.
Quick check
Submodule
Monitoring, Complications, Cycling, and Transition
Monitoring connects what was prescribed and infused to nutrition response, metabolic tolerance, organ effects, catheter safety, and readiness to use the gut.
- Early and ongoing monitoring
- Refeeding and glycemic safety
- PN-associated complications
- Cycling, home PN, and transition
Watch phosphate, potassium, magnesium, fluid, and glycemia
→Weight, intake, output, liver, kidney, triglycerides, and line
→Change hourly exposure carefully and monitor starts and stops
→Reduce PN as oral or enteral delivery becomes reliable
Monitor by phase and acuity
At initiation, assess glucose, sodium, potassium, magnesium, phosphate, fluid balance, kidney function, and signs of refeeding at a frequency matched to risk. Continue weight, intake and output, nutrient delivery, triglycerides, liver tests, blood counts, clinical examination, catheter site, and infectious signs. Stable home therapy can use longer intervals, but only after trends and responsibilities are established.
Separate overfeeding from intolerance
Hyperglycemia, hypertriglyceridemia, excess carbon dioxide production, fluid retention, and hepatic abnormalities can reflect excessive energy delivery, illness, medicines, or impaired metabolism. Review all calories and infusion rates before adding treatments solely to accommodate an excessive prescription. Regular insulin may be added to PN under a validated protocol, but changing requirements can create hypoglycemia risk.
Prevent and detect long-term complications
Long-term PN can contribute to cholestasis, steatosis, biliary disease, metabolic bone disease, micronutrient deficiency or accumulation, and catheter complications. Avoid overfeeding, preserve enteral stimulation when possible, cycle selected stable patients, use an appropriate lipid strategy, and monitor targeted laboratory and clinical findings rather than applying one fixed panel forever.
Cycle and transition with intent
Cyclic PN provides a daily infusion-free period and can support home routines, but it increases hourly glucose, fluid, and nutrient exposure. Start and stop procedures are individualized; universal tapering is not required for every stable adult. As oral or enteral delivery becomes reliable, reduce PN while measuring actual gastrointestinal intake and tolerance. Home PN requires trained patients or caregivers, a coordinated team, supplies, emergency planning, and safe catheter care.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 100 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- ASPEN parenteral nutrition clinical resources and care pathway
- ASPEN guidance on parenteral nutrition indications and appropriateness
- ASPEN update on in-line filters for parenteral nutrition
- ASPEN adult lipid injectable emulsion safety recommendations
- FDA current SMOFlipid prescribing information
- USP chapter 797 sterile compounding standards
- CDC intravascular catheter infection prevention guidance
- ASPEN consensus recommendations for refeeding syndrome